The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Cytokine Targets & Treatment Developments for Psoriatic Arthritis & Spondyloarthritis

Cytokine Targets & Treatment Developments for Psoriatic Arthritis & Spondyloarthritis

March 15, 2021 • By Carina Stanton

  • Tweet
  • Email
Print-Friendly Version / Save PDF
rumruay / shutterstock.com

rumruay / shutterstock.com

ACR CONVERGENCE 2020—In recent years, a pathophysiological role for the interleukin (IL) 17/IL-23 axis in the development of psoriasis, enthesitis and inflammatory arthritis has been investigated in both rodent and human models. Clinical trials have demonstrated differential benefits for skin disease and joint disease in patients with psoriatic arthritis, axial spondyloarthritis (axSpA) and ankylosing spondylitis (AS). 

You Might Also Like
  • Management of Psoriatic Arthritis, Treatment of Axial Spondyloarthritis Addressed at EULAR 2016
  • New Guideline: NSAIDs Effective in Treating Ankylosing Spondylitis & Nonradiographic Axial Spondyloarthritis
  • Ustekinumab Improves Spondylitis in Patients with Psoriatic Arthritis
Explore This Issue
March 2021
Also By This Author
  • Long-Term Canakinumab Treatment Has Favorable Effect on Systemic Features & Joint Health for sJIA

During the session IL-17, IL-23 and Other Cytokine Targets: Lessons from Clinical Trials for Spondyloarthritis, two investigators reviewed the recent literature and shared emerging insights regarding cytokine-targeting therapies for various disease manifestations in spondyloarthritis. 

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Christopher Ritchlin, MD, MPH, professor and chief of the Allergy/Immunology and Rheumatology Division, University of Rochester Medical Center, New York, discussed the genetic basis for susceptibility to the development of spondylo­arthritis and shared current research insights on the clinical benefits of blocking IL-17/IL-23 axis pathways to treat patients with psoriatic arthritis. 

Joerg Ermann, MD, an instructor in medicine at Harvard Medical School, Boston, and a researcher and rheuma­tologist at Brigham and Women’s Hospital, Boston, discussed the development and current trajectory for cytokine-targeting therapies used to treat axSpA.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Cytokine Targets in Psoriatic Arthritis

Dr. Ritchlin

Dr. Ritchlin

Dr. Ritchlin, a principal investigator for several clinical trials testing the efficacy of agents in the treatment of psoriatic and rheumatoid arthritis and AS, explained that the IL-17/IL-23 axis has both IL-17-dependent and IL-17-independent path­ways. In the IL-17-dependent pathway, IL-23 released by dendritic cell macro­phages can activate the differentiation of T helper 17 (Th-17) cells through retinoid-related orphan receptor γt, releasing a variety of important cytokines, including IL-17A and IL-17F, as well as IL-22, that can influence a number of other cell types. 

In the IL-17-independent pathway, IL-23 interacts with its receptor on a variety of cell sites. These interactions can promote a number of critical events in these cells, including angiogenesis, recruitment of cells and infiltration of activated Th-17 and IL-2 cells. Dr. Ritchlin noted, “These pathways really make a difference, particularly when you are looking at therapeutics.”

It’s important to recognize that IL-17 molecules in a number of isoforms, Dr. Ritchlin stated. These isoforms include a homodimer (IL-17A) and a heterodimer (IL-17F) that bind to specific receptors. Receptor engagement results in downstream activation of P38, and subsequent transcription of NF-κB and activator protein 1 activation (AP-1). These transcription factors promote the production of a variety of pro- and anti-inflammatory molecules. He also emphasized that Th-17 cells can be pro­inflammatory, anti-inflammatory or regulatory, and the microenvironment they are found in can help drive a cell in a certain direction, “so just seeing that a cell expresses the signature of an IL-17 helper cell does not necessarily tell you the function of that cell.”

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

In a brief review of the genetic basis of psoriatic arthritis from the perspective of IL-23, Dr. Ritchlin shared work by Stuart et al. comparing genetic SNPs of patients with psoriatic arthritis.1 He highlighted the potential associations of genetic snips with abnormalities in the IL-17/IL-23 axis.

Pages: 1 2 3 4 5 | Single Page

Filed Under: Conditions, Spondyloarthritis Tagged With: ACR Convergence 2020, Ankylosing Spondylitis, AS Resource Center, IL-17/IL-23 Cytokine, Janus Kinase Inhibitors, PsA Resource Center, Psoriatic ArthritisIssue: March 2021

You Might Also Like:
  • Management of Psoriatic Arthritis, Treatment of Axial Spondyloarthritis Addressed at EULAR 2016
  • New Guideline: NSAIDs Effective in Treating Ankylosing Spondylitis & Nonradiographic Axial Spondyloarthritis
  • Ustekinumab Improves Spondylitis in Patients with Psoriatic Arthritis
  • A New Treatment for Axial Spondyloarthritis?

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.